The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
India sales grew 23.5% YoY with consolidation of Wockhardt products
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Dr. Reddy's has the rights to distribute 250mn doses in India
The facility is expected to be completed in 2024
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
Subscribe To Our Newsletter & Stay Updated
